Zydus Lifesciences Limited announced an extension in the timeline for completing the acquisition of the Active Pharmaceutical Ingredient (API) business of Sterling Biotech Limited, reinforcing its strategy to strengthen API manufacturing capabilities.
Expanding API Manufacturing Portfolio
The proposed acquisition involves the transfer of Sterling Biotech’s API business assets, which include manufacturing infrastructure and product portfolio. This move is aimed at enhancing Zydus’ position in the bulk drug segment and expanding its API production footprint.
By acquiring established API facilities, the company seeks to improve supply chain integration and strengthen its presence in both domestic and global markets.
Strategic Focus on API Capacity Expansion
The acquisition aligns with Zydus’ broader strategy of expanding its API manufacturing capabilities to support its formulation business and external supply opportunities.
This expansion will enable the company to:
- Increase production capacity for key APIs
- Improve backward integration
- Enhance competitiveness in regulated and semi-regulated markets
Transaction Timeline and Extension
The Business Transfer Agreement (BTA) for the acquisition was originally signed on September 17, 2024. However, the timeline for completion has been extended multiple times due to pending regulatory approvals and fulfillment of conditions precedent.
The latest extension moves the completion deadline to June 30, 2026, providing additional time to finalize the transaction.
Strengthening API Supply Chain Integration
The acquisition is expected to support Zydus’ long-term goal of achieving greater vertical integration across the pharmaceutical value chain. By strengthening its API base, the company can ensure better control over raw material sourcing and production efficiency.
This is particularly important in the current environment, where pharmaceutical companies are focusing on supply chain resilience and reduced dependency on external suppliers.
Outlook
This development highlights a growing trend of consolidation and strategic acquisitions in the API sector. Companies are increasingly investing in API manufacturing assets to enhance production capabilities and secure long-term supply chains.
With this move, Zydus Lifesciences Limited is positioning itself as a stronger player in the API market while expanding its manufacturing base and global competitiveness.
